NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

SNK01 is an autologous, non-genetically modified natural killer (NK) cell product that has enhanced cytotoxicity and activating receptor expression. This approved trial of 30 patients with moderate Alzheimer’s Disease will look to commence before the end of this year.